An Indirect Comparison Between Nivolumab + Ipilimumab + Two Cycles of Chemotherapy vs. Pembrolizumab + Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer

An Indirect Comparison Between Nivolumab + Ipilimumab + Two Cycles of Chemotherapy vs. Pembrolizumab + Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer

BackgroundNivolumab + ipilimumab + two cycles chemotherapy (N-I + chemo, intensive immunotherapy but chemo-light) and pembrolizumab + chemotherapy (Pem + chemo) were both recommended as first-line treatment for metastatic non-small cell lung carcinoma (NSCLC) patients. We conducted this indirect com...

Full description

Bibliographic Details
Main Authors: Panpan Jiang, Ziyang Mao, Qinyang Wang, Xiaohui Jia, Luying Geng, Hong Xu, Lili Jiang, Chengcheng Yang, Min Jiao, Hui Guo
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Oncology
Subjects:
pembrolizumab
nivolumab
ipilimumab
non-small cell lung cancer
efficacy
safety
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.698199/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.698199/full

Similar Items